Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which forecasts that growth in the pharmaceutical market in Brazil, Russia, India and China (BRIC) will be slow, but steady.
The Market for Pharmaceuticals in Brazil, Russia, India & China describes expansion in these regions as evolution rather than revolution. While the report takes into account that these are rapidly emerging economies, which in 2006 represented a market of over 2.7 billion people and a combined GDP of $5.2 trillion, it also notes that the BRIC countries’ total projected health expenditure in 2006 was estimated at US$266.2 billion. This sum is equivalent to what Germany spent on healthcare on its own and it overshadowed by the sum the U.S. spent on healthcare in the same time frame – $2.1 trillion.
Of the BRIC countries, China presently has the largest expenditure on healthcare totalling $137 billion in 2006. The report predicts that average annual growth in China’s expenditure is estimated at 11% to 2011, taking the total to US$412.8 billion. The Russian pharmaceutical market was estimated at US$5.1 billion and it is expected to reach US$9.5 billion by 2011. Projected growth is fastest in India, at 15.3%, and slowest in Brazil, at 3.7%.
Authors of the report point out that unlike in the developed countries where there is a somewhat uniform level of spend on healthcare, there are wide regional variations in expenditure levels in the BRIC countries. All four countries possess a wealthy urban population with a much higher spending power than the national average. If these countries can enable more people to attain the wealth of the middle classes, then higher levels of healthcare are bound to be more affordable, predict the analysts.
The study identifies the key drivers in the four markets and also compares and contrasts economic, health and pharmaceutical operating environments in the regions. It also has a detailed analysis of the health structure, funding, service and outlook for the individual markets.
The report contains information on the rating key areas such generic drugs, pricing and IP. It provides an overview of the regulatory environment, distribution guides and trade fair information in the region. It also has provides the contact details of key healthcare organisations and trade associations.
Report Buyer product ID: ESP00071
